GLP -1 booster

Abstract

The invention relates to a composition containing i) a DPP-4 inhibitor selected from an extract of dandelion (Taraxacum officinale), an extract of white mulberry (Morus alba), an extract of bitter melon (Momordica charantia), a hydrolysate of yeast (Saccharomyces cerevisiae), an extract of garlic (Allium sativum), an extract of grape (Vitis vinifera), an extract of turmeric (Curcuma longa), an extract of horseradish tree (Moringa oleifera) and an extract of fenugreek (Trigonella foenum-graecum); and ii) a GLP-1 analogue selected from a hydrolysate from yeast (Saccharomyces cerevisiae), an extract of white mulberry (Morus alba), an extract of Yerba mate (Ilex paraguariensis), an extract of Arabica coffee (Coffea arabica), an extract of purslane (Portulaca oleracea), an extract of bitter melon (Momordica charantia), an extract of queen's crape myrtle (Lagertroemia speciosa), an extract of apple (Malus domestica), an extract of cinnamon (Cinnamomum verum) and an extract of fenugreek (Trigonella foenum-graecum); and iii) a GLP-1 secretion promoter selected from inulin, gum arabic, an extract of bitter melon (Momordica charantia), an extract of purslane (Portulaca oleracea), an extract of common barberry (Berberis vulgaris), an extract of arabica coffee (Coffea arabica), an extract of Dahurian angelica (Angelica dahurica), an extract of turmeric (Curcuma longa) and an extract of fenugreek (Trigonella foenum-graecum), wherein, from each group i)-iii), at least one ingredient is selected and in total at least three different ingredients are selected.

Description

[0001] PM International AG August 29, 2025

[0002] M / PMINT-065-PC

[0003] ZE / TP / tp

[0004] GLP-1 BOOSTER

[0005] Description

[0006] The invention relates to a composition that can be used as a food supplement or foodstuff, and its use.

[0007] Increased food production and supply have improved living conditions for a large part of the population. However, undesirable effects, such as obesity, have also emerged. Obesity is perceived negatively by some individuals for purely aesthetic or emotional reasons. Therefore, there has long been a need for products that help control body weight, reduce appetite, create a feeling of satiety, and lower calorie intake.

[0008] With the aim of meeting this need, several products, including dietary supplements, have been developed, although there is still room for improvement.

[0009] In response to food intake, two peptide hormones, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), are released from the intestine. These hormones have a direct stimulatory effect on the beta cells of the pancreas, increasing insulin secretion. It is well known that oral glucose intake triggers a greater insulin release than intravenous administration—a phenomenon known as the "incretin effect."

[0010] Physiological effects of GLP-1 include glucose-dependent stimulation of insulin secretion, thus lowering blood glucose levels; inhibition of glucagon secretion, thus inhibiting glycogenolysis; inhibition of gastric emptying, thus increasing satiety; inhibition of food intake and reducing appetite, as well as weight loss. M / PMINT-065-PC

[0011] 2

[0012] In recent years, a number of substances have been developed that can also be used as antidiabetic drugs and / or for weight control. These substances target the GLP-1 axis, both as GLP-1 receptor agonists and as inhibitors of dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for the rapid inactivation of GLP-1 in the bloodstream. Examples of GLP-1 receptor agonists include semaglutide (Ozempic, Ribelsus, Wegovy) and liraglutide (Saxenda, Victoza).

[0013] However, these substances, like long-established dietary supplements, also have disadvantages, such as side effects, poor compliance, low bioavailability, weak efficacy, and / or high costs. There is also a need for natural alternatives, particularly those derived from plants and / or fungi.

[0014] Against this background, an object of the present invention is to provide a composition that overcomes disadvantages in the prior art. In particular, the composition should preferably produce at least one effect selected from i) controlling body weight, ii) reducing appetite, iii) creating a feeling of satiety, and iv) reducing calorie intake.

[0015] Summary of the invention

[0016] The efforts to solve this problem resulted, in a first aspect, in a composition containing i) a DPP-4 inhibitor selected from an extract of dandelion (Taraxacum officinale), an extract of white mulberry (Morus alba), an extract of bitter melon (Momordica charantia), a hydrolysate of yeast (Saccharomyces cerevisiae), an extract of garlic (Allium sativum), an extract of grape (Vitis vinifera), an extract of turmeric (Curcuma longa), an extract of horseradish tree (Moringa oleifera), and an extract of fenugreek (Trigonella foenum-graecum); and ii) a GLP-1 analogue selected from a hydrolysate of yeast (Saccharomyces cerevisiae), an extract of white mulberry (Morus alba), an extract of yerba mate (Ilex paraguariensis), an extract of Arabica coffee (Coffea arabica), an extract of purslane (Portulaca oleracea), an M / PMINT-065-PC

[0017] 3

[0018] Extract of bitter melon (Momordica charantia), an extract of queen flower (Lagerstroemia speciosa), an extract of apple (Malus domestica), an extract of cinnamon (Cinnamomum verum) and an extract of fenugreek (Trigonella foenum-graecum); and iii) a GLP-1 secretion enhancer selected from inulin, gum arabic, an extract of bitter melon (Momordica charantia), an extract of purslane (Portulaca oleracea), an extract of common barberry (Berberis vulgaris), an extract of Arabica coffee (Coffea arabica), an extract of Siberian angelica (Angelica dahurica), an extract of turmeric (Curcuma longa) and an extract of fenugreek (Trigonella foenum-graecum), wherein at least one ingredient is selected from each group i)-iii) and a total of at least three different ingredients are selected.

[0019] The efforts to solve this task also result in a composition, optional according to the first aspect, containing an extract of dandelion (Taraxacum officinale), a hydrolysate of yeast (Saccharomyces cerevisiae) and an extract of bitter melon (Momordica charantia).

[0020] The efforts to solve this task also result in a composition, optional according to the first aspect, containing an extract of dandelion (Taraxacum officinale), an extract of white mulberry (Morus alba) and an extract of bitter melon (Momordica charantia).

[0021] The efforts to solve this problem also resulted in a capsule comprising a capsule shell and a composition according to the invention, wherein the capsule shell contains a cellulose ether.

[0022] The underlying concept of the invention is to provide a combination of at least three naturally derived substances, in particular those derived from plants and / or fungi, including a DPP-4 inhibitor, a GLP-1 analogue, and a GLP-1 secretion enhancer. The combination of these ingredients can achieve at least one effect selected from: i) controlling body weight, ii) reducing appetite, iii) creating a feeling of satiety, iv) reducing calorie intake, and v) reducing blood glucose spikes. According to the invention, a GLP-1 analogue is a substance that has a similar physiological effect to GLP-1 but lacks the M / PMINT-065-PC

[0023] 4

[0024] The GLP-l receptor is not directly activated, which is a distinguishing feature compared to synthetic GLP-l receptor agonists.

[0025] The invention also relates to the use of a composition and / or a capsule according to the invention to achieve at least one effect selected from i) controlling body weight, ii) reducing appetite, iii) creating a feeling of satiety, iv) reducing calorie intake and v) reducing blood sugar spikes.

[0026] The invention also relates to a method for achieving at least one effect selected from i) controlling body weight, ii) reducing appetite, iii) creating a feeling of satiety, iv) reducing calorie intake and v) reducing blood sugar spikes, wherein a composition and / or a capsule according to the invention is taken orally.

[0027] Detailed description of the invention

[0028] The composition is preferably a dietary supplement and / or a food product.

[0029] Preferably, the composition contains an extract of dandelion (Taraxacum officinale). Preferably, the dandelion extract (Taraxacum officinale) is an extract from dandelion leaves. Preferably, it is a dry extract, preferably with a drug-extract ratio of 3:1 to 5:1. It has been found that the dandelion extract can act as a DPP-4 inhibitor and, in particular, in the combination according to the invention, can contribute to achieving the described effect.

[0030] Preferably, the composition contains an extract of bitter melon (Momordica charantia). Preferably, the bitter melon (Momordica charantia) extract is an extract from the fruit of the bitter melon. Preferably, it is a dry extract. Preferably, the extract contains at least 5% by weight of bitter substances, for example, 5% to 15% by weight. Bitter melon extract has been found to be a DPP-4 inhibitor, a GLP-1 analogue, and a GLP-1 receptor agonist (M / PMINT-065-PC).

[0031] 5

[0032] secretion promoters can act and, in particular, in the combination according to the invention, can contribute to achieving the described effect.

[0033] Preferably, the composition contains a yeast (Saccharomyces cerevisiae) hydrolysate. Preferably, the yeast (Saccharomyces cerevisiae) hydrolysate is a peptide-rich hydrolysate. In the peptide-rich hydrolysate, peptides may be concentrated at < 10,000 Da, so that the hydrolysate consists of approximately 60 wt% protein and approximately 33 wt% carbohydrates. It has been found that the yeast hydrolysate can act as a DPP-4 inhibitor and a GLP-1 analogue and, in particular, in the combination according to the invention, can contribute to achieving the described effect.

[0034] Preferably, the composition contains an extract of purslane (Portulaca oleracea). Preferably, the purslane extract (Portulaca oleracea) is an extract from the aerial parts of the purslane plant. Preferably, it is a dry extract, preferably with a drug-extract ratio of 3:1 to 5:1. It has been found that the purslane extract can act as a GLP-1 analogue and GLP-1 secretion enhancer and, in particular, in the combination according to the invention, can contribute to achieving the described effect.

[0035] Preferably, the composition contains a bioenhancer. Bioenhancers can increase the bioavailability of orally administered substances. The presence of one or more bioenhancers allows the composition according to the invention to realize a nutrient transport concept (NTC). The bioenhancer is preferably an extract of ginger (Zingiber officinale). In other words, the composition preferably contains an extract of ginger (Zingiber officinale). Preferably, the ginger (Zingiber officinale) extract is an extract from the rhizomes of ginger. Preferably, it is a dry extract, preferably with a drug-to-extract ratio of 3:1 to 5:1. Preferably, the extract is a CO2 extraction extract.

[0036] Preferably the composition contains zinc, preferably zinc gluconate.

[0037] Preferably, the composition contains a filler, preferably selected from gum arabic and inulin, or mixtures thereof. Gum M / PMINT-065-PC

[0038] 6. Gum arabic and inulin can have a high fiber content, which acts as dietary fiber. Gum arabic from acacia trees, e.g., with CAS No. 9000-01-5, is suitable, for example. It has been found that gum arabic and inulin can act as GLP-1 secretion enhancers and, in particular, in the combination according to the invention, can contribute to achieving the described effect.

[0039] Preferably, the composition contains an extract of white mulberry (Morus alba). Preferably, the white mulberry (Morus alba) extract is an extract from the leaves of the white mulberry. Preferably, it is a dry extract, preferably with a 1-DNJ (1-deoxynojirimycin) content of approximately 1.5% to 5% by weight based on the total weight of the dry extract. It has been found that the white mulberry extract can act as a DPP-4 inhibitor and a GLP-1 analogue and, in particular, in the combination according to the invention, can contribute to achieving the described effect.

[0040] In a preferred embodiment, the composition contains an extract of common barberry (Berberis vulgaris). Preferably, the common barberry (Berberis vulgaris) extract is an extract from the fruit of the common barberry. Preferably, it is a dry extract, preferably with a berberine content of at least 1% by weight based on the total weight of the dry extract, for example, from 1% by weight to 3% by weight. It has been found that the common barberry extract can act as a GLP-1 secretion enhancer and, in particular, in the combination according to the invention, can contribute to achieving the described effect.

[0041] In a preferred embodiment, the composition contains an extract of Arabica coffee (Coffea arabica). Preferably, the Arabica coffee (Coffea arabica) extract is an extract of green Arabica coffee beans. Preferably, it is a dry extract, preferably with a drug-to-extract ratio of 8:1 to 14:1. Preferably, the extract contains, based on the total weight of the dry extract, at least 35 wt.% to 55 wt.% chlorogenic acid and 2 wt.% to 7 wt.% caffeine. The extraction solvent used to prepare the extract can be a mixture of ethanol and water, for example, a mixture of 80% ethanol with 20% water, wherein the extraction solvent is evaporated after extraction to yield a dry extract.

[0042] 7. The same applies to the extraction agent and method for the other extracts disclosed herein. It has been found that the extract from Arabica coffee can act as a GLP-1 analogue and GLP-1 secretion enhancer and, in particular, in the combination according to the invention, can contribute to achieving the described effect.

[0043] In a preferred embodiment, the composition contains an extract from the yerba mate shrub (Ilex paraguariensis). Preferably, the yerba mate (Ilex paraguariensis) extract is an extract from the leaves of the yerba mate shrub. Preferably, it is a dry extract, preferably with a caffeine content of approximately 0.5% to 5% by weight based on the total weight of the dry extract. The extraction solvent used to produce the extract can consist of water. It has been found that the yerba mate extract can act as a GLP-1 analogue and, in particular, in the combination according to the invention, can contribute to achieving the described effect.

[0044] In a preferred embodiment, the composition comprises an extract of dandelion (Taraxacum officinale), an extract of white mulberry (Morus alba), an extract of bitter melon (Momordica charantia), a hydrolysate of yeast (Saccharomyces cerevisiae), an extract of yerba mate (Ilex paraguariensis), an extract of Arabica coffee (Coffea arabica), an extract of purslane (Portulaca oleracea), a filler selected from gum arabic and inulin and mixtures thereof, an extract of ginger (Zingiber officinale) and

[0045] Zinc gluconate. It was found that the combination according to the invention is suitable for achieving at least one effect selected from i) controlling body weight, ii) reducing appetite, iii) creating a feeling of satiety, iv) reducing calorie intake and v) reducing blood sugar spikes.

[0046] In another preferred embodiment, the composition contains an extract of dandelion (Taraxacum officinale), an extract of white mulberry (Morus alba), an extract of bitter melon (Momordica charantia), M / PMINT-065-PC

[0047] 8 a hydrolysate of yeast (Saccharomyces cerevisiae), an extract of common barberry (Berberis vulgaris), an extract of purslane (Portulaca oleracea), a bulking agent selected from gum arabic and inulin and mixtures thereof, an extract of ginger (Zingiber officinale) and

[0048] Zinc gluconate. It was found that the combination according to the invention is suitable for achieving at least one effect selected from i) controlling body weight, ii) reducing appetite, iii) creating a feeling of satiety, iv) reducing calorie intake and v) reducing blood sugar spikes.

[0049] The capsule shell according to the invention contains a cellulose ether. Preferably, the cellulose ether comprises hydroxypropylmethylcellulose.

[0050] The use according to the invention is preferably non-medical, in particular as a dietary supplement and / or food. In the use according to the invention, it is preferred that the composition or capsule is taken orally before a meal, preferably 5 to 60 minutes before the meal. Preferably, the composition or capsule is administered orally three times a day. The composition can also be divided into several capsules. For example, healthy individuals can take two capsules each before breakfast, lunch, and dinner.

[0051] In a preferred embodiment of the use according to the invention, per day

[0052] 0.01 g to 0.2 g of an extract from dandelion (Taraxacum officinale),

[0053] 0.01 g to 0.5 g of an extract from white mulberry (Morus alba),

[0054] 0.05 g to 0.5 g of an extract of bitter melon (Momordica charantia), 0.25 g to 1.0 g of a hydrolysate of yeast (Saccharomyces cerevisiae), 0.05 g to 0.5 g of an extract of yerba mate (Ilex paraguariensis), 0.1 g to 0.5 g of an extract of Arabica coffee (Coffea arabica), 0.01 g to 0.5 g of an extract of purslane (Portulaca oleracea),

[0055] 0.5 g to 5 g of a filler selected from gum arabic and inulin, and mixtures thereof,

[0056] 0.001 g to 0.01 g of an extract of ginger (Zingiber officinale) and M / PMINT-065-PC

[0057] 9

[0058] 0.001 g to 0.05 g zinc gluconate administered orally.

[0059] In a further preferred embodiment of the use according to the invention, per day

[0060] 0.01 g to 0.2 g of an extract from dandelion (Taraxacum officinale),

[0061] 0.01 g to 0.5 g of an extract from white mulberry (Morus alba),

[0062] 0.05 g to 0.5 g of an extract from bitter melon (Momordica charantia),

[0063] 0.25 g to 1.0 g of a hydrolysate from yeast (Saccharomyces cerevisiae),

[0064] 0.01 g to 0.2 g of an extract from common barberry (Berberis vulgaris),

[0065] 0.01 g to 0.5 g of purslane extract (Portulaca oleracea),

[0066] 0.5 g to 5 g of a filler selected from gum arabic and inulin, and mixtures thereof,

[0067] 0.001 g to 0.01 g of an extract of ginger (Zingiber officinale) and

[0068] 0.001 g to 0.05 g zinc gluconate administered orally.

[0069] The method according to the invention is preferably a non-medical method. The descriptions regarding the use according to the invention apply.

[0070] The embodiments within this document can be combined with one another as desired, unless the subject matter and the description of the embodiments clearly indicate otherwise.

[0071] The verbs “contain” and “encompass” and their conjugations also include the verb “consist of” with its conjugations.

[0072] The invention is illustrated below by means of examples which are not intended to be limiting.

[0073] Example 1

[0074] Size 00 capsules are filled with a composition such that each capsule

[0075] 0.017 g of an extract from dandelion leaves (Taraxacum officinale), 0.067 g of an extract from bitter melon fruit (Momordica charantia), M / PMINT-065-PC

[0076] 10

[0077] Contains 0.083 g of a hydrolysate of yeast (Saccharomyces cerevisiae), the remainder being gum arabic. The capsule shell contains hydroxypropyl methylcellulose.

[0078] Example 2

[0079] Size 00 capsules are filled with a composition such that each capsule

[0080] 0.017 g of an extract from dandelion leaves (Taraxacum officinale),

[0081] 0.050 g of an extract from the leaves of the white mulberry (Morus alba),

[0082] Contains 0.067 g of an extract from the fruit of the bitter melon (Momordica charantia), and gum arabic. The capsule shell contains hydroxypropyl methylcellulose.

[0083] Example 3

[0084] Size 00 capsules are filled with a composition such that each capsule

[0085] 0.017 g of an extract from dandelion leaves (Taraxacum officinale),

[0086] 0.050 g of an extract from the leaves of the white mulberry (Morus alba),

[0087] 0.067 g of an extract from the fruit of the bitter melon (Momordica charantia),

[0088] 0.083 g of a hydrolysate from yeast (Saccharomyces cerevisiae),

[0089] 0.013 g of an extract from the leaves of the yerba mate shrub (Ilex paraguariensis),

[0090] 0.050 g of an extract from green beans of Arabica coffee (Coffea arabica),

[0091] 0.030 g of an extract from the aerial parts of purslane (Portulaca oleracea),

[0092] 0.2 g gum arabic,

[0093] 0.001 g of an extract from the rhizomes of ginger (Zingiber officinale) and

[0094] Contains 0.002 g zinc gluconate. The capsule shell contains hydroxypropyl methylcellulose.

[0095] Example 4

[0096] Size 00 capsules are filled with a composition such that each capsule

[0097] 0.017 g of an extract from dandelion leaves (Taraxacum officinale),

[0098] 0.050 g of an extract from the leaves of the white mulberry (Morus alba), M / PMINT-065-PC

[0099] 11

[0100] 0.067 g of an extract from the fruit of the bitter melon (Momordica charantia), 0.083 g of a hydrolysate from yeast (Saccharomyces cerevisiae),

[0101] 0.017 g of an extract from the fruit of the common barberry (Berberis vulgaris),

[0102] 0.030 g of an extract from the aerial parts of purslane (Portulaca oleracea),

[0103] 0.2 g gum arabic,

[0104] Contains 0.001 g of an extract from ginger rhizomes (Zingiber officinale) and 0.002 g of zinc gluconate.

[0105] Example 5

[0106] Healthy subjects take two capsules each 30 minutes before breakfast, lunch and dinner, as described in examples 1-4, over a longer period of time.

[0107] The application resulted in at least one effect in some of the test subjects, selected from better control of body weight, a reduction in appetite and calorie intake, and the creation of a feeling of satiety.

Claims

M / PMINT-065-PC 12 Claims 1. Composition, containing i) a DPP-4 inhibitor selected from an extract of dandelion (Taraxacum officinale), an extract of white mulberry (Morus alba), an extract of bitter melon (Momordica charantia), a hydrolysate of yeast (Saccharomyces cerevisiae), an extract of garlic (Allium sativum), an extract of grape (Vitis vinifera), an extract of turmeric (Curcuma longa), an extract of horseradish tree (Moringa oleifera), and an extract of fenugreek (Trigonella foenum-graecum);and ii) a GLP-1 analogue selected from a hydrolysate of yeast (Saccharomyces cerevisiae), an extract of white mulberry (Morus alba), an extract of yerba mate (Ilex paraguariensis), an extract of Arabica coffee (Coffea arabica), an extract of purslane (Portulaca oleracea), an extract of bitter melon (Momordica charantia), an extract of lager flower (Lagerstroemia speciosa), an extract of apple (Malus domestica), an extract of cinnamon (Cinnamomum verum) and an extract of fenugreek (Trigonella foenum-graecum);and iii) a GLP-1 secretion enhancer selected from inulin, gum arabic, an extract of bitter melon (Momordica charantia), an extract of purslane (Portulaca oleracea), an extract of common barberry (Berberis vulgaris), an extract of Arabica coffee (Coffea arabica), an extract of Siberian angelica (Angelica dahurica), an extract of turmeric (Curcuma longa) and an extract of fenugreek (Trigonella foenum-graecum), wherein at least one ingredient is selected from each group i)-iii) and a total of at least three different ingredients are selected.; 2. Composition, optionally according to claim 1, comprising an extract of dandelion (Taraxacum officinale), an extract of bitter melon (Momordica charantia) and a hydrolysate of yeast (Saccharomyces cerevisiae).

3. Composition according to any of the preceding claims, characterized in that M / PMINT-065-PC 13 the composition contains an extract of purslane (Portulaca oleracea).

4. A composition according to any of the preceding claims, characterized by the fact that the composition contains a bioenhancer.

5. Composition according to any of the preceding claims, characterized by the fact that the composition contains an extract of ginger (Zingiber officinale).

6. Composition according to any of the preceding claims, characterized by the fact that the composition contains zinc, preferably zinc gluconate.

7. Composition according to any of the preceding claims, characterized by the fact that the composition contains gum arabic.

8. Composition according to any of the preceding claims, characterized by the fact that the composition contains an extract of white mulberry (Morus alba).

9. Composition according to any of the preceding claims, characterized by the fact that the composition contains an extract of common barberry (Berberis vulgaris).

10. Composition according to any of the preceding claims, characterized by the fact that the composition contains an extract of Arabica coffee (Coffea arabica).

11. Composition according to any of the preceding claims, wherein indicated that M / PMINT-065-PC 14 the composition contains an extract of mate shrub (Ilex paraguariensis).

12. Composition according to any of the preceding claims, characterized in that the composition contains inulin.

13. Capsule comprising a capsule shell and a composition according to any of the preceding claims, wherein the capsule shell contains a cellulose ether.

14. Use of a composition according to any of the preceding claims and / or a capsule according to the preceding claim to achieve at least one effect selected from i) controlling body weight, ii) reducing appetite, iii) creating a feeling of satiety, iv) reducing calorie intake and v) reducing blood sugar spikes.

15. Use of a composition according to the preceding claim, wherein the composition and / or the capsule is taken twice daily before meals.